LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy

Not Recruiting

Trial ID: NCT05366699


Lymphedema is a chronic, progressive, and debilitating condition that occurs with disruption or obstruction of the lymphatic system, which commonly occurs a result of breast cancer therapy. The purpose of this study is to determine if the use of a low risk lymphatic reconstruction procedure at the time of axillary lymph node dissection will reduce the risk of developing lymphedema. Additionally, to determine if this procedure improves objective outcomes of lymphedema and patient quality of life

Official Title

A Randomized Clinical Trial of the LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy

Stanford Investigator(s)

Irene Wapnir, MD
Irene Wapnir, MD

Professor of Surgery (General Surgery)

Frederick M. Dirbas, MD
Frederick M. Dirbas, MD

Associate Professor of Surgery (General Surgery)

Kimberly Stone, MD
Kimberly Stone, MD

Clinical Assistant Professor, Surgery - General Surgery

Jacqueline Tsai, MD, FACS
Jacqueline Tsai, MD, FACS

Clinical Associate Professor, Surgery - General Surgery


Inclusion Criteria:

   - Ages 18 to 75 years (inclusive)

   - Patients undergoing unilateral or bilateral breast cancer related axillary

   - Free of distant metastasis in preoperative screening

   - Histology results of axillary lymph nodes could be either Negative or Positive

   - Patients who undergo preoperative chemotherapy can be included

   - Willingness and ability to provide written informed consent

   - Willingness and ability to comply with all study procedures

Exclusion Criteria:

   - Primary lymphedema of the affected upper limb

   - Secondary lymphedema of the affected limb prior to the lymphadenectomy

   - Radiotherapy at the axilla before the study / surgery

   - Allergic reaction to porcine collagen or ICG

   - Receiving radiation therapy to the involved nodal basin in a period less than 4 weeks
   after the surgery

   - Concurrent participation in a clinical trial of any other investigational drug or
   therapy, regardless of indication, within 1 month before screening

   - Other medical condition that could lead to limb edema, such as (but not limited to
   primary lymphedema or acute venous thrombosis

   - Other medical condition that could result in symptoms overlapping those of lymphedema
   in the affected limb (e.g., pain, swelling, decreased range of motion)

   - Either of the following, at the time of baseline evaluation: ipsilateral:contralateral
   limb volume ratio>1.1 or R0 bioimpedance ratio > 1.106 when the nondominant limb is at
   risk, and 1.134 when the dominant limb is at risk.

   - Life expectancy < 2 years for any reason

   - Pregnancy or nursing

   - Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening

   - Severe psychiatric disease

   - Significant or chronic renal insufficiency (defined as serum creatinine > 2.5 mg/dL or
   an estimated glomerular filtration rate [eGFR] < 30 mL/min at screening) or requires
   dialytic support

   - Hepatic dysfunction, defined as alanine transaminase (ALT) or aspartate transaminase
   (AST) levels > 3 × upper limit of the normal range (ULN) and/or bilirubin level > 2 ×
   ULN at screening

   - Absolute neutrophil count < 1500 mm3 at screening

   - Hemoglobin concentration < 9 g/dL at screening

   - Any reason (in addition to those listed above) that, in the opinion of the
   investigator, precludes full participation in the study


procedure: Axillary lymphadenetomy alone

procedure: axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Dung Nguyen, MD, PharmD

New Trial Alerts

Receive email alerts when trials open to patients.